@article{22a85ca5fe374aa19f683b0212c2a983,
title = "Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab",
abstract = "In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.",
keywords = "Adolescent, Adult, Aged, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Humanized, Female, Humans, Integrin alpha4, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting",
author = "S{\o}rensen, {Per Soelberg} and Jensen, {Poul Erik Hyldgaard} and Aiden Haghikia and Malin Lundkvist and Christian Vedeler and Finn Sellebjerg and Nils Koch-Henriksen and Anna Fogdell-Hahn and Kjell-Morten Myhr and Jan Hillert and Ralf Gold",
year = "2011",
doi = "10.1177/1352458511404271",
language = "English",
volume = "17",
pages = "1074--8",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "Sage Science Press (UK)",
number = "9",
}